97 related articles for article (PubMed ID: 2243978)
1. Receptor imaging: application to MR imaging of liver cancer.
Reimer P; Weissleder R; Lee AS; Wittenberg J; Brady TJ
Radiology; 1990 Dec; 177(3):729-34. PubMed ID: 2243978
[TBL] [Abstract][Full Text] [Related]
2. Asialoglycoprotein receptor function in benign liver disease: evaluation with MR imaging.
Reimer P; Weissleder R; Lee AS; Buettner S; Wittenberg J; Brady TJ
Radiology; 1991 Mar; 178(3):769-74. PubMed ID: 1994416
[TBL] [Abstract][Full Text] [Related]
3. Experimental hepatocellular carcinoma: MR receptor imaging.
Reimer P; Weissleder R; Brady TJ; Yeager AE; Baldwin BH; Tennant BC; Wittenberg J
Radiology; 1991 Sep; 180(3):641-5. PubMed ID: 1871273
[TBL] [Abstract][Full Text] [Related]
4. MR receptor imaging: ultrasmall iron oxide particles targeted to asialoglycoprotein receptors.
Weissleder R; Reimer P; Lee AS; Wittenberg J; Brady TJ
AJR Am J Roentgenol; 1990 Dec; 155(6):1161-7. PubMed ID: 2122660
[TBL] [Abstract][Full Text] [Related]
5. Specific targeting of breast tumor by octreotide-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 3.0-Tesla magnetic resonance scanner.
Li X; Du X; Huo T; Liu X; Zhang S; Yuan F
Acta Radiol; 2009 Jul; 50(6):583-94. PubMed ID: 19449236
[TBL] [Abstract][Full Text] [Related]
6. [Synthesis of Gal-BSA-SPIO and magnetic resonance imaging of ASG receptors in rabbits bearing liver VX2 tumor and human liver].
Jia FG; Zhang XD; Xu YK; Meng Z
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Feb; 29(2):191-4. PubMed ID: 19246275
[TBL] [Abstract][Full Text] [Related]
7. Dynamic signal intensity changes in liver with superparamagnetic MR contrast agents.
Reimer P; Kwong KK; Weisskoff R; Cohen MS; Brady TJ; Weissleder R
J Magn Reson Imaging; 1992; 2(2):177-81. PubMed ID: 1562768
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow: ultrasmall superparamagnetic iron oxide for MR imaging.
Senéterre E; Weissleder R; Jaramillo D; Reimer P; Lee AS; Brady TJ; Wittenberg J
Radiology; 1991 May; 179(2):529-33. PubMed ID: 2014305
[TBL] [Abstract][Full Text] [Related]
9. Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227).
Saini S; Edelman RR; Sharma P; Li W; Mayo-Smith W; Slater GJ; Eisenberg PJ; Hahn PF
AJR Am J Roentgenol; 1995 May; 164(5):1147-52. PubMed ID: 7717222
[TBL] [Abstract][Full Text] [Related]
10. Liver tumors in cirrhosis: experimental study with SPIO-enhanced MR imaging.
Clement O; Frija G; Chambon C; Schouman-Clayes E; Mosnier JF; Poupon MF; Balkau B
Radiology; 1991 Jul; 180(1):31-6. PubMed ID: 2052718
[TBL] [Abstract][Full Text] [Related]
11. Use of magnetite particles as a contrast agent for MR imaging of the liver.
Kawamura Y; Endo K; Watanabe Y; Saga T; Nakai T; Hikita H; Kagawa K; Konishi J
Radiology; 1990 Feb; 174(2):357-60. PubMed ID: 2296645
[TBL] [Abstract][Full Text] [Related]
12. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging.
Weissleder R; Elizondo G; Wittenberg J; Lee AS; Josephson L; Brady TJ
Radiology; 1990 May; 175(2):494-8. PubMed ID: 2326475
[TBL] [Abstract][Full Text] [Related]
13. Use of an asialoglycoprotein receptor-targeted magnetic resonance contrast agent to study changes in receptor biology during liver regeneration and endotoxemia in rats.
Leveille-Webster CR; Rogers J; Arias IM
Hepatology; 1996 Jun; 23(6):1631-41. PubMed ID: 8675187
[TBL] [Abstract][Full Text] [Related]
14. Receptor-directed contrast agents for MR imaging: preclinical evaluation with affinity assays.
Reimer P; Weissleder R; Wittenberg J; Brady TJ
Radiology; 1992 Feb; 182(2):565-9. PubMed ID: 1732982
[TBL] [Abstract][Full Text] [Related]
15. Hepatocyte-targeted MR contrast agents: contrast enhanced detection of liver cancer in diffusely damaged liver.
Tanimoto A; Kuribayashi S
Magn Reson Med Sci; 2005; 4(2):53-60. PubMed ID: 16340158
[TBL] [Abstract][Full Text] [Related]
16. A functionalized superparamagnetic iron oxide colloid as a receptor directed MR contrast agent.
Josephson L; Groman EV; Menz E; Lewis JM; Bengele H
Magn Reson Imaging; 1990; 8(5):637-46. PubMed ID: 1707120
[TBL] [Abstract][Full Text] [Related]
17. [Superparamagnetic iron particles. The clinical results in the MR diagnosis of liver metastases].
Ham B; Reichel M; Vogl T; Taupitz M; Wolf KJ
Rofo; 1994 Jan; 160(1):52-8. PubMed ID: 8305693
[TBL] [Abstract][Full Text] [Related]
18. Targeting of ultrasmall superparamagnetic iron oxide (USPIO) particles to tumor cells in vivo by using transferrin receptor pathways.
Kresse M; Wagner S; Pfefferer D; Lawaczeck R; Elste V; Semmler W
Magn Reson Med; 1998 Aug; 40(2):236-42. PubMed ID: 9702705
[TBL] [Abstract][Full Text] [Related]
19. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging.
Weissleder R; Elizondo G; Wittenberg J; Rabito CA; Bengele HH; Josephson L
Radiology; 1990 May; 175(2):489-93. PubMed ID: 2326474
[TBL] [Abstract][Full Text] [Related]
20. Arabinogalactan-coated superparamagnetic iron oxide: effect of particle size in liver MRI.
Wisner ER; Amparo EG; Vera DR; Brock JM; Barlow TW; Griffey SM; Drake C; Katzberg RW
J Comput Assist Tomogr; 1995; 19(2):211-5. PubMed ID: 7890843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
